# BioSciCon Consortium

*BioSciCon, Inc.*
*Johns Hopkins University, MCC*
*9605 Medical Center Drive, Suites 109C and 109D*
*Rockville, MD 20850*
*Tel: 301-610-9130 Fax: 301-610-7662*
*E-mail:info@bioscicon.com*
*www.bioscicon.com*

**BioSciCon, Inc.**, The Biomedical Science Consulting Company is women-owned biotechnology R&D organization incorporated in 1996 with primary focus on the development of a proprietary platform MarkPap® technology for improvement of cytological early detection of cervical cancer and making it affordable, accessible and available world-wide. The other three entities of the **Consortium** are **MarkPap LLC, MarkPap Pacific LLC and MarkPap India LLC** for commercialization of MarkPap® products as they emerge from R&D phase (www.bioscicon.com). **The Global Academy for Women's Health, Inc.** is an independent non-profit organization with a mission to promote excellence in women's health science and education, which integrates prior and current non-profit activities of BioSciCon founders continuing their legacy to work for public benefit (www.markpap.com).

*Olivera Markovic, MD, PhD*
*Founding Director of BioSciCon*

**BioSciCon** designs and develops patented biomarker-based MarkPap® technology products. Biomarker is exclusively present in abnormal cervical cells. When visualized with MarkPap test, it appears as a red pigment flagging abnormal cells not to be missed even by a low-trained person. Detecting abnormal cells on time makes a difference between life and death, since cervical cancer is a preventable disease if detected on time, but deadly if allowed to develop. The first generation MarkPap® products are MarkPap® Reagent Kit with accessories (MarkPap Solution, COMBO Control Slides) for manual and automated slide processing (MarkPap® Auto). The second generation is MarkPap® Digital for digital transmission of images from the point-of-care to distant centers for expert diagnosis. The third generation includes MarkPap® Self (specimen's self-collecting Kit) and MarkPap® Wireless for wireless transmission of images.

## BioSciCon's MarkPap® Technology


The biomarker is not only contributing to the test to be more accurate, faster and less expensive test more affordable for women, but its presence allows the low-trained person at the point-of- care to recognize abnormal cells and transmit their images for distant reading (telecytopathology). The MarkPap® Self provides screening benefit to women who do not have access to medical institutions or those who avoid visiting gynecologist. MarkPap® Wireless is to allow the images to be captured and transmitted with cell phone from anywhere in the world. Currently, there are about 520,000 new cases of cervical cancer diagnosed each year globally and 260,000 women die from a preventable disease in the 21st Century. Less than 10% women at average participate in cervical cancer screening. MarkPap technology can make a difference.

MarkPap® products are available for licensing and sales under local regulations.